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Abstract
Background: Over the last 15 years, hand, foot, and mouth disease (HFMD) has emerged as a major public health
burden across the Asia-Pacific region. A small proportion of HFMD patients, typically those infected with enterovirus 71
(EV71), develop brainstem encephalitis with autonomic nervous system (ANS) dysregulation and may progress rapidly to
cardiopulmonary failure and death. Although milrinone has been reported to control hypertension and support
myocardial function in two small studies, in practice, a number of children still deteriorate despite this treatment.
Magnesium sulfate (MgSO4) is a cheap, safe, and readily available medication that is effective in managing tetanus-
associated ANS dysregulation and has shown promise when used empirically in EV71-confirmed severe HFMD cases.
Methods/Design: We describe the protocol for a randomized, placebo-controlled, double-blind trial of intravenous
MgSO4 in Vietnamese children diagnosed clinically with HFMD plus ANS dysregulation with systemic hypertension. A
loading dose of MgSO4 or identical placebo is given over 20 min followed by a maintenance infusion for 72 h according
to response, aiming for Mg levels two to three times the normal level in the treatment arm. The primary endpoint is a
composite of disease progression within 72 h defined as follows: development of pre-specified blood pressure criteria
necessitating the addition of milrinone, the need for ventilation, shock, or death. Secondary endpoints comprise these
parameters singly, plus other clinical endpoints including the following: requirement for other inotropic agents; duration
of hospitalization; presence of neurological sequelae at discharge in survivors; and neurodevelopmental status assessed
6 months after discharge. The number and severity of adverse events observed in the two treatment arms will also be
compared. Based on preliminary data from a case series, and allowing for some losses, 190 patients (95 in each arm) will
allow detection of a 50 % reduction in disease progression with 90 % power at a two-sided 5 % significance level.
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Discussion: Given the large numbers of HFMD cases currently being seen in hospitals in Asia, if MgSO4 is shown to be
effective in controlling ANS dysregulation and preventing severe HFMD complications, this finding would be important to
pediatric care throughout the region.
Trial registration: ClinicalTrials.gov Identifier: NCT01940250 (Registered 22 August 2013).
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Background
Hand, foot, and mouth disease (HFMD) is a common in-
fectious disease, primarily affecting young children, caused
by a number of enteroviruses belonging to the species
Human enterovirus A and including coxsackievirus a16
(CA16) and enterovirus 71 (EV71). Infection with EV71 is
of particular concern because it can cause severe HFMD,
sometimes resulting in death. Over the past 15 years,
EV71-associated HFMD has emerged across Asia, with
outbreaks thought to involve millions of people occurring
in the region [1]. EV71-related HFMD has also increased
markedly in Vietnam during this period, and in 2011, 170
deaths occurred among the 113,000 Vietnamese children
clinically diagnosed with the disease [2].
Autonomic nervous system (ANS) dysregulation and
HFMD
During outbreaks, thousands of children can develop
HFMD, and although most will have self-limited illness
with fever and rash only, a small proportion will develop
neurological and systemic complications that can be rap-
idly fatal. Neurological manifestations of EV71 infection
include aseptic meningitis and acute flaccid paralysis,
but the issue of most concern is brainstem encephalitis
because autonomic nervous system (ANS) dysregulation
may occur, potentially with rapid progression to cardio-
pulmonary failure [1]. Clinical features indicating ANS
dysregulation include high persistent fever, profuse
sweating, mottled skin, tachycardia, tachypnoea, hyper-
tension, and hyperglycemia [3]. The Vietnamese Ministry
of Health (MoH) has developed guidelines for clinical
staging and suggested management of HFMD, according
to the severity grade (Additional file 1: Appendix 1).
Briefly, Grade 1 represents classic HFMD without com-
plications. Patients with Grade 2 disease show some evi-
dence of central nervous system involvement, usually
manifesting as myoclonus. In Grade 3 disease, evidence
of ANS dysfunction is present, whereas patients with
Grade 4 disease have cardio-pulmonary compromise.
Although the mechanisms underlying the ANS dysreg-
ulation have not been clearly defined, evidence exists
that inflammation occurs in the medulla oblongata and
cervical spinal cord, causing increased sympathetic activ-
ity and resulting in severe systemic and pulmonary
hypertension and eventually pulmonary edema [1]. The
frequency of ANS dysregulation is also unclear because
many of the signs are rather subjective and also can be
present among children with high fever; however, the
development of systemic hypertension in children with
HFMD is considered to be unequivocal evidence of ANS
dysregulation. The frequency with which this occurs is
not known, however, because only severe cases are usu-
ally reported. In one study of 36 severe EV71 infection
cases from Taiwan, more than 36 % developed systemic
hypertension, whereas in 22 severe HFMD cases re-
ported from China, 17 cases had hypertension [4].
Research has also revealed left ventricular dysfunction
in patients with EV71-associated brainstem encephal-
itis/hypertension who later develop pulmonary edema.
Although no histological or virological evidence of viral
myocarditis was seen, catecholamine-associated cardio-
toxic effects were found on histological examination of
cardiac ventricular biopsies, together with high concen-
trations of norepinephrine and epinephrine in plasma
from these patients [5]. Thus, high plasma catechol-
amine concentrations secondary to brainstem encephal-
itis are purported to have a direct effect on cardiac
function, as well as to cause pulmonary edema by rais-
ing pulmonary pressures [1]. Alternatively, or in
addition, the impact of altered cytokine profiles on the
cardiopulmonary system may influence the severity of
HFMD [6]. In small studies, the severity of EV71 infec-
tion has been associated with altered concentrations of
a number of different cytokines, including TNF∝, INFγ,
IL6, and IL13, in blood and cerebrospinal fluid (CSF),
with evidence that cytokine levels correlate with the de-
gree of injury to the brainstem and spinal ganglia [7].
Moreover, in a number of animal studies of neurogenic
hypertension, associations have been demonstrated
between inflammatory cytokine levels and enhanced
vasomotor and cardiac sympathetic drive [8].
Management of ANS dysregulation
Management of ANS dysregulation presents particular
challenges. In one report from Taiwan, use of the
phosphodiesterase-3 inhibitor, milrinone was said to
control hypertension and support myocardial function in
a group of 24 children with severe HFMD compared to
historical controls [9]. In addition, milrinone was shown
to decrease mortality in HFMD patients with pulmonary
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edema in a small, open-label, randomized clinical trial in
Vietnam [10]. On the basis of these small studies, milri-
none has now become the recommended therapy for
HFMD with ANS dysregulation in Vietnam, with MoH
guidelines setting down indications for when the drug
should be commenced in suspected HFMD cases. Cur-
rently, the MoH guidelines define the intervention level
for use of milrinone to be when the systolic blood pres-
sure (SBP) exceeds the 99th percentile for age plus
5 mmHg, which approximates to the internationally
accepted definition of Stage 2 hypertension in children
(Additional file 1: Appendix 1) [11]. However, clinical
failures still occur despite high dose intravenous milri-
none, and a number of children go on to require hemo-
filtration and ventilatory support, the next steps
recommended in the Vietnamese MoH guidelines (Add-
itional file 1: Appendix 2). Secondly, there are few clin-
ical or safety data available with respect to milrinone use
in children, apart from a few small studies following car-
diac surgery [12] [13]. Recent reports suggest that milri-
none use is an independent risk factor for clinically
significant tachyarrhythmia after congenital heart sur-
gery, and may be associated with development of acute
renal failure [13].
Magnesium sulfate and ANS dysregulation
Autonomic disinhibition is also postulated to occur in se-
vere tetanus. Elevated concentrations of circulating cate-
cholamines have been observed, and urinary epinephrine
and norepinephrine excretion are increased proportional
to disease severity [14, 15]. In a randomized controlled
trial comparing magnesium sulfate (MgSO4) with placebo
in patients with severe tetanus, the use of magnesium was
associated with significantly reduced requirements for
drugs to control muscle spasms and cardiovascular in-
stability [16]. In patients undergoing tracheal intubation
or surgery for pheochromocytoma, the use of magnesium
was associated with a reduction in SBP and in plasma cat-
echolamine concentrations [17]. Isolated reports exist of
rapid and effective control of life-threatening autonomic
hyperreflexia in patients with spinal cord lesions [18–22].
In in vitro studies, magnesium has been shown to reduce
catecholamine secretion from the peripheral nerve end-
ings and the adrenal medulla [23]. Intrapartum use of
MgSO4 in women with preeclampsia was associated with
reduced cytokine levels in the women and their babies
[24]. Similarly, the use of magnesium in a small number
of patients with aneurysmal subarachnoid hemorrhage
was associated with reduced serum levels of certain in-
flammatory cytokines [25]. Formal safety data relating to
the use of MgSO4 in pediatric care are limited, but from
its use in children with severe asthma [18] and in a small
number of neonates with uncontrolled pulmonary hyper-
tension [26], adverse effects appear to be infrequent.
In summary, although HFMD has become one of the
major contributors to childhood morbidity and mortal-
ity in Vietnam, current management strategies rely on
guidelines that are based on expert opinion and only
two small clinical studies. Vietnamese MoH guidelines
currently indicate that milrinone should be used when
Stage 2 hypertension develops, but evidence for the ef-
ficacy of this intervention is limited, and a number of
children (approximately 20 %, personal communication
Dr. Phan Tu Qui) treated in this way require additional
interventions. In addition, milrinone is an expensive
drug with a known toxicity profile and requires highly
experienced staff to administer it. We hypothesized that
early intervention with MgSO4 in Grade 3 HFMD,
when Stage 1 hypertension and ANS dysregulation first
become apparent, might control cardiovascular instabil-
ity more effectively and prevent progression to more
severe disease. MgSO4 is cheap, readily available, and
generally considered to be safe. Given the very large
numbers of HFMD cases currently being seen in hospi-
tals in Asia, if MgSO4 is shown to be effective in con-
trolling ANS dysregulation and preventing severe
HFMD complications, this finding would be important
to pediatric care throughout the Asian region.
Primary objective of the trial
The primary objective of the trial is to evaluate the effects
of MgSO4 for the control of hypertension and progression
to severe disease (shock, respiratory compromise, or death)
in children with severe HFMD and ANS dysregulation.
Secondary objectives of the trial
The secondary objectives of the trial are as follows:
1. To describe the clinical signs of autonomic
dysfunction observed in children with severe
HFMD; measure levels of biomarkers of
sympathetic activity, including plasma and urine
catecholamine levels and levels of inflammatory
cytokines; and to assess the impact of MgSO4 on
these parameters.
2. To examine the relations between measures of
cardiac output (CO) and systemic vascular
resistance (SVR) with clinical signs of autonomic
dysfunction and to assess the impact of MgSO4 on
these parameters.
3. To evaluate the effects of MgSO4 on long-term out-
come from severe HFMD in survivors, by assessing
neurodevelopmental status at 6 months.
Methods/Design
Study Design
This is a randomized, placebo-controlled, double-blind
trial to assess the efficacy and side effect profile of
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intravenous MgSO4 when used in Vietnamese children
with clinically diagnosed HFMD and signs of ANS dys-
regulation with systemic hypertension.
Study sites
The Hospital for Tropical Diseases (HTD) and Children’s
Hospital Number One (CH1) are two major hospitals in
Ho Chi Minh City, Vietnam, with 1600 in-patient beds in
total. Each hospital functions as a first-level facility for the
immediate local population and as a tertiary referral cen-
ter responsible for the diagnosis and management of ser-
ious infectious diseases for a population of over 15 million
children across southern Vietnam. The Oxford University
Clinical Research Unit (OUCRU) is located on the HTD
site, and together, the three institutions have established a
number of fruitful research collaborations over more than
20 years.
Inclusion and exclusion criteria (see Additional file 1:
Appendices 1-4 for definitions/additional details)
Vietnamese MoH guidelines indicate that all suspected
HFMD cases with Grade 2 or more severe disease should
be admitted to a Pediatric Intensive Care Unit (PICU) or
High Dependency Unit (HDU) facility for close observa-
tion. The guidelines also indicate that a peripheral arterial
line should be inserted for invasive BP monitoring if there
are any signs of ANS dysfunction. For patients with Grade
3 disease (that is, the group eligible for inclusion in this
study), the pulse, BP, respiratory rate and pattern, oxygen
saturation, and temperature must be monitored very
closely, and the child should receive intravenous sedation
with phenobarbitone, as well as a dose of 1 g/kg intraven-
ous immunoglobulin (IVIG) as soon as possible, with a
second dose of IVIG 24 h later.
All patients aged 6 months to 15 years admitted to the
PICU at HTD or the HDU on the Infectious Diseases
Ward at CH1 in Ho Chi Minh City with clinically sus-
pected HFMD (Additional file 1: Appendix 1) are con-
sidered for eligibility for this trial. Patients are eligible
for enrollment if a) the arterial blood pressure (BP),
measured via an indwelling catheter, exceeds the inter-
nationally recognized definition for Stage 1 hypertension
in children (Additional file 1: Appendix 3) [27]; b) they
exhibit at least one other criterion for ANS dysregula-
tion (Additional file 1: Appendix 4), such as tachypnea
for age, irregular or labored breathing but with oxygen
saturation above 92 % in air and a normal arterial blood
gas, resting heart rate sustained above 150 beats/minute,
mottled skin, profuse sweating, refractory fever, or
hyperglycemia; and c) no contraindications to study in-
clusion are present, including a past history of hyperten-
sion, chronic renal, cardiac or pulmonary disease, or any
neurological disorder; features indicating a current
hypertensive emergency (see below); treatment with
milrinone or any other inotropic agent has already com-
menced; respiratory distress is present with oxygen sat-
uration below 92 % in air or an arterial pCO2 over
45 mmHg; atrioventricular block or any arrhythmia
(other than sinus tachycardia) is present on an ECG
rhythm strip, or the QT interval is prolonged; or
reduced urine output or increased creatinine levels indi-
cate renal compromise. If the patient fulfils these criteria
and a parent or guardian gives written informed consent
(see “Ethical Considerations” section), then the child is
enrolled in the study.
The current Vietnamese MoH guidelines specify that
milrinone should be given to children with HFMD and
ANS dysregulation when the SBP is sustained at a level
exceeding a value approximating the 99th percentile for
age plus 5 mmHg (that is, Stage 2 hypertension) with
the intention that treatment should commence within 1
to 2 h [28]. Enrollment to this study is designed to be
early, when hypertension is first identified (at Stage 1),
so that in the event of treatment failure, the MoH treat-
ment guidelines can be applied. A small number of
patients who present with Stage 2 hypertension may also
be enrolled; in such cases, very stringent BP criteria will
ensure that, if the BP does not improve within 30 min of
commencing the study drug, milrinone will be added.
That is, all Stage 2 patients will be on milrinone within
1 h of presentation unless the BP falls to Stage 1 levels.
Intervention / study medication
Detailed information on the use of MgSO4, the
pharmacokinetics, the side effects profile, etc. is pro-
vided in Additional file 1: Appendix 5. Patients are
assigned to one of two treatment arms and follow the
same dosing schedule in both arms. After written in-
formed consent has been obtained, staff administer a
loading dose of 50 mg/kg of either MgSO4 or a visually
matched placebo (sterile water) by continuous infusion
into a peripheral intravenous line over 20 min, followed
by a maintenance infusion in the treatment arm of 30
to 50 mg/kg/h for 72 h according to response, aiming
for plasma Mg levels two to three times the normal
level. All staff members involved in the clinical care re-
main blind to the treatment allocation, and Mg levels
are monitored and adjusted by independent doctors
from another clinical facility as detailed in the section
on “dose adjustment” below.
Study endpoints
The primary endpoint is a composite endpoint indicating
disease progression within 72 h. It is defined as the oc-
currence of any of the following within 72 h of commen-
cing the study drug infusion:
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1. Specific BP criteria necessitating the addition of
milrinone as detailed in the section “Criteria for the
addition of milrinone” below.
2. Need for mechanical ventilation.
3. Development of shock.
4. Death.
Secondary endpoints comprise these parameters singly,
plus a number of other clinical endpoints including the
following: a requirement for other inotropic agents (for
example, dobutamine), duration of hospitalization, pres-
ence of neurological sequelae at discharge in survivors,
and neurodevelopmental status assessed 6 months after
discharge.
Safety endpoints include the number of adverse events
(AEs) and severe adverse events (SAEs) that occur in the
two treatment arms.
Exploratory endpoints will be assessed, including serial
measurements of cardiac output (CO) and systemic
vascular resistance (SVR), catecholamine levels, and
cytokine levels. We will assess the impact of MgSO4 on
these parameters, provided the data collected appear
reliable and consistent within individual participants.
Criteria for the addition of milrinone
Milrinone will be commenced in any of the following cir-
cumstances to ensure compliance with the Vietnamese
MoH guidelines for management of HFMD:
1. Hypertensive emergency, which includes a severe
symptomatic elevation in BP (>30 % compared to
baseline BP) WITH evidence of acute target organ
damage, for example, brain (seizures or increased
intracranial pressure), kidneys (renal insufficiency),
eyes (papilledema, retinal hemorrhages, or exudates),
or heart (heart failure).
2. For children aged 1 year and older:
a. SBP increases to ≥ 99th percentile plus between 5
and 15 mmHg consistently for 30 min.
b. SBP increases to ≥ 99th percentile plus 15 mmHg
consistently for 15 min
c. SBP increases to ≥ 40 mmHg over baseline for
15 min and this value is lower than either of the
first two cut-offs. The baseline SBP is defined as
the lowest value measured at any time after admis-
sion to hospital before enrollment in the study.
3. For children aged 6 months to 1 year:
a. SBP increases to ≥ 110 mmHg up to 120 mmHg
consistently for 30 min.
b. SBP increases to ≥ 120 mmHg consistently for
15 min.
Occasionally, the clinical status of a patient may indi-
cate that milrinone is not the best inotrope to use. In
these cases, the treating physician will make manage-
ment decisions appropriate to the situation. Similarly, if
the patient’s clinical status remains unstable after start-
ing milrinone, additional measures, including ventilation
and/or hemofiltration, will be considered in accordance
with Vietnamese MoH guidelines for management of
HFMD (Additional file 1: Appendix 2). If the BP remains
high (SBP > 99th percentile plus > 15 mmHg) despite
maximal doses of milrinone and study drug infusion,
then additional antihypertensive agents may be added,
such as nicardipine, captopril, etc. depending on the
clinical scenario.
Study procedures
Screening and recruitment of participants (Fig. 1)
Phase 1 (HTD only) Initially, recruitment is scheduled
to take place at one site (HTD) only to ensure that all
study procedures run smoothly during the first few
months. Study staff working on PICU at HTD will identify
parents or guardians of potentially eligible patients as soon
as possible after admission. They consult the hospital
chart and the parents/guardians to verify if the initial
screening criteria are met, then provide the patient infor-
mation sheet (PIS, see Additional file 1: Appendix 7) and
discuss the study with relevant families. This allows time
for the family members to consider the study without
pressure to decide immediately. A reference card is com-
pleted at this time, defining the specific intra-arterial BP
thresholds needed for study enrollment, the addition of
milrinone, treatment failure, etc. relevant to that particular
individual (by age, sex and length), and this card is at-
tached to the child’s observation chart at the bedside. If
the child subsequently develops autonomic disturbance
with hypertension exceeding the defined threshold, the
study staff go through the PIS a second time with the fam-
ily and answer any questions before asking for consent,
then follow the full pathway for inclusion/exclusion cri-
teria, and if appropriate, proceed to enrollment and
randomization (Fig. 1). A case report form (CRF) detailing
the history and examination findings at enrollment is
completed as soon as the study drug infusion has been
started. Children whose parents/guardians do not consent
to the study continue with standard care.
Occasionally, patients may present with established
Stage 2 hypertension; these individuals have arterial ac-
cess established immediately, and the process of
explaining the study, requesting consent, checking in-
clusion/exclusion criteria and proceeding to enrolment
and randomization, if appropriate, is carried out as
quickly as possible, with the aim of commencing the
study drug within 30 min. If the BP does not improve
within 30 min of commencing the study drug, the mil-
rinone is added. That is, all Stage 2 patients will be on
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≤Fig. 1 Screening flow chart
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milrinone within 1 h of presentation unless the BP has
settled to Stage 1 levels with the study drug.
In case worry over the child’s illness could affect the par-
ents/guardians ability to make an informed decision on
study participation, a study doctor goes though the PIS with
the family of all participants at least once more in the 12 to
36 h after enrollment or at any time they ask. This review
of the PIS is recorded in the CRF.
Phase 2 (HTD and CH1) The study will be established
and executed in a similar manner on the HDU at CH1
in due course, with both sites aiming to complete the re-
cruitment over 2 to 3 years.
Randomization and blinding
Randomization follows a 1:1 ratio, stratified according
to the hospital where recruitment takes place. A
randomization list using block randomization with blocks
of variable size has been prepared by the Clinical Trial
Pharmacist using a computer program and is maintained
confidentially from all study staff and treating doctors, in-
cluding those assessing all trial outcomes. A chronological
log of all enrolled patients is maintained by the Pharmacist
and the next available sequential study code is assigned to
each patient as they enroll. The assigned number corre-
sponds to a coded, sealed, package containing 50
ampoules of 15 % MgSO4 or visually matched placebo.
Dispensing, storage and accountability
MgSO4 15 % solution and placebo (sterile water) are
available in 10 ml visually matched ampoules supplied
by Fresenius Kabi. Study drug packages are prepared
centrally by the un-blinded Clinical Trials Pharmacist
and distributed to the sites as required. Drugs are stored
in accordance with the manufacturers’ recommendations
in a secure area. All movements of study medication are
recorded. Both individual subject and overall drug ac-
countability records are kept up to date. Prior to admin-
istration each vial is diluted with 5 ml 0.9 % saline
solution by trained study nurses, to give a volume of
15 ml and provide a 10 % MgSO4 solution for the mag-
nesium intervention arm.
Study drug dose adjustment (Fig. 2)
After the initial loading dose, the study infusion dose is
increased in 0.1 ml/kg/h stages (10 mg/kg/h) every 15 min
to a maximum dose of 0.5 ml/kg/h (50 mg/kg/h), with the
following caveats:
 If the SBP decreases to < 90th percentile for age, sex,
and length, the study drug infusion is reduced by
one stage every 15 min.
 If the SBP increases to the levels described below for
treatment failure, action is taken as indicated.
 Plasma Mg levels are measured at least once daily. If
the plasma Mg level is > 2.5 mmol/l or < 1.8 mmol/l,
an increase or decrease in the infusion rate by
0.1 ml/kg/h is implemented as appropriate. To
maintain blinding, plasma Mg values are
communicated by the laboratory staff to an
independent doctor not involved in the clinical care
of the patient, who informs the clinical staff of any
dose adjustments to be made to the study drug
infusion but does not report the actual laboratory
values. Similar (sham) dose adjustments are made
for the placebo infusions according to a randomized
list available only to the independent doctor.
However, the clinicians managing the patient may
request unblinding at any time.
Discontinuation of the study treatment
If any of the following occur, the study treatment is
stopped immediately, and rescue treatment is given as
appropriate (Additional file 1: Appendix 5, 6):
1. Serious cardiac arrhythmia (for example, atrio-
ventricular block, prolonged QT interval)
2. Hypotension: SBP < 70 + (2 × age) mmHg for 15 min
or more
3. Urine output < 1 ml/kg/h for 4 h or more
4. Cardiac arrest or any other emergency situation
where the treating physician feels there is a contra-
indication to the study drug.
In addition, if a patient develops respiratory distress
(as defined in Additional file 1: Appendix 4), an urgent
plasma Mg level will be performed. If intubation and
ventilation is needed or if the Mg level is > 3 mmol/l,
the study treatment will be stopped, and rescue treat-
ment will be given as described in Additional file 1:
Appendix 6.
Unblinding
The Clinical Trials Pharmacist holds the unblinded
randomization list with details of the contents of each
individual treatment package. This list will be accessed
only in the case of emergency unblinding, which will be
authorized by an investigator following standard oper-
ating procedures. Emergency unblinding will be per-
formed in the case of an adverse event when knowledge
of the identity of the study treatment may contribute to
the treating physician’s ability to care for the patient. In
this case, the treating doctor will confirm with the Prin-
cipal Investigator that unblinding may help inform the
care of the patient. If agreed on by the Principal Inves-
tigator, the treating doctor may request to know the
Mg/Ca lab results or may open the sealed emergency
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Fig. 2 Treatment flow chart
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envelopes available on the ward that contain individual
patient treatment allocations. In general, in these cases,
the study treatment would already have been discontin-
ued as per the “Discontinuation of study treatment”
paragraph.
Clinical assessments and follow-up (Additional file 1: Appen-
dix 8)
All participants remain in the study for the duration of
follow-up to 6 months unless the parent/guardian wishes
to withdraw, which they may do at any time (see with-
drawal section, page 28). In addition to the study proce-
dures outlined below, all patients will receive standard
care according to the national treatment guidelines. Dur-
ing the acute phase, patients are examined daily by
trained HDU/PICU study doctors. A record of all signifi-
cant events in the previous 24 h plus detailed physical
examination findings (in particular focusing on the ner-
vous system, respiratory, and cardiovascular systems) is
recorded each morning in the specially designed CRF.
Vital signs are monitored continuously using devices
with the facility for download and recording of data into
a readable database format using compatible software
and/or accessory modules. In a subset of patients, ad-
vanced hemodynamic parameters such as CO and SVR
are recorded using LiDCO monitoring systems, the sub-
set being determined by the availability of the LiDCO
technology at the time when an individual is enrolled
and randomized.
A standard ECG recording is performed at the bedside
by a trained nurse once daily and also if any abnormality
is noted on the monitor by study staff (for example, pre-
mature beats, or atrial or ventricular arrhythmias). Urine
output is monitored using specific collecting bags and
calculated every 4 h. If the urine output is less than
1 ml/kg/h over a 4-h period, a bedside ultrasound scan
is done, and if necessary, urethral catheterization is
established to monitor the urine output more closely.
Magnesium is an important cofactor in many en-
zymatic reactions in the body, but the side effect pro-
file is well known, and in the dose range used here, it
is generally considered safe (Additional file 1: Appen-
dix 5). However, differentiation between potential
magnesium toxicity and progression of HFMD can be
difficult. All staff involved in the study have been
trained to recognize potential side effects, and a series
of standard operating procedures have been put in
place indicating when to stop study treatment and/or
initiate rescue therapy if any complications occur that
might be related to the treatment (Additional file 1:
Appendix 6). Similarly, all staff members are aware
that they may request an urgent Mg/Ca level at any
time or request emergency unblinding in the case of
any adverse event when knowledge of the identity of
the study treatment might contribute to the treating
physician’s ability to care for the patient.
Patients are assessed daily for the duration of the hospital
stay. At discharge, full neurological and neurodevelopmental
assessments are performed. Patients who have not recovered
fully from the effects of sedation with phenobarbitone by the
time of discharge, but are otherwise considered fit to go home,
are asked to attend 1 week later for formal review and neuro-
logical assessment. All patients are also asked to return at
6 months post-enrollment for a clinical and neurodevelopmen-
tal assessment. After this, any further follow-up will be accord-
ing to clinical need, and participants will be referred back to
the standard hospital outpatient clinic system.
Neurodevelopmental assessments done at discharge
(or 1 week later) and 6 months use the Bayley Scales of
Infant Development, Third Edition (Bayley-III) and
Movement ABC-2 tools. Children 36 months and under
at enrollment will use the Bayley-III. Children 48 months
and above at enrollment will use the Movement ABC-2
tool for their assessments.
Laboratory assessments and diagnostic testing
The following laboratory tests (see Additional file 1:
Appendix 9) are performed on site in the standard hos-
pital laboratories or at the research laboratory of
OUCRU in Ho Chi Minh City, except where specifically
indicated below:
1. Blood glucose and arterial blood gases are measured
at least once daily or more frequently according to
the clinical situation.
2. Plasma magnesium and calcium concentrations are
measured at baseline and 12 h after the start of the
study infusion, then once daily for the remaining
72 h.
3. Plasma electrolytes, creatinine, CKMB and Troponin
I are measured at baseline and once daily thereafter.
4. Samples for plasma catecholamine (epinephrine and
norepinephrine) concentrations are collected at
baseline and then once daily for 72 h, and stored
frozen for subsequent analysis in batches. Similarly,
a 5-ml aliquot of urine is collected each morning for
measurement of urine catecholamines. All urine is
collected in appropriate collecting bottles (containing
10 to 15 ml 6 M HCl as preservative) by the bedside
and the total volume is recorded at the end of the
24-h period, before the 5-ml aliquot is taken for
storage at −20 °C.
5. Samples for plasma cytokine measurements
(including IL1, IL6, IL13, and TNF alpha) are
collected and stored at −20 °C at baseline and at
12 h and 24 h after starting the MgSO4/placebo,
with a final sample obtained on discharge from
hospital.
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6. A nasal/throat swab and a rectal swab are obtained
at enrollment, for enterovirus PCR.
7. Serological testing for EV71 and related serotypes
within the Human enterovirus A species will be
done on plasma samples collected at enrolment and
discharge. This work will be done in collaboration
with laboratories at Duke-NUS in Singapore.
8. With separate consent, cells from participant plasma
samples are separated and stored for assessment of
host genetic factors associated with disease severity
using exome sequencing at The Wellcome Trust
Sanger Institute, UK.
Adverse Events
Any unfavorable or unexpected sign, including an abnor-
mal laboratory finding, which develops or worsens after
commencing the study drug infusion, is documented as
an Adverse Event (AE). All clinical AEs are recorded on
an AE form, but laboratory abnormalities are only en-
tered on an AE Form if they are accompanied by clinical
symptoms, lead to withdrawal of the study drug or
modification of the study drug dose, or require a change
in concomitant therapy.
Serious Adverse Event (SAEs) are defined as those
that result in death, are life threatening at the time, re-
quire prolongation of existing hospitalization (>14 days,
Additional file 1: Appendix 4), or lead to persistent or
significant disability/incapacity.
All SAEs are reported to a) OUCRU as the Sponsor
and b) the IRB at the relevant site (HTD or ND1) as
soon as possible. A report of any SAE that is life threat-
ening or that results in death is also sent to the office of
the Vietnamese MoH Research Ethics Committee. These
reports are sent within 7 days of knowledge of the event
and include details of the event and the recommenda-
tion from the site IRB. If all information is not available
upon the initial report, a complete report is sent within
15 days of knowledge of the event. All other SAEs are
reported to the MoH Research Ethics Committee, in-
cluding the recommendation of the site ethical commit-
tee, within 15 days of knowledge of the event.
Data management
Source data
Source documents are original documents, data, and re-
cords from which participants’ study data are obtained.
These include, but are not limited to, hospital records (from
which medical history and previous and concurrent medi-
cation may be summarized into the CRF), digital or printed
laboratory and pharmacy records, MRI data files and digital
or printed output from monitoring devices. CRF entries are
considered source data if the CRF is the site of the original
recording (that is, no other written or electronic records of
the data exist). In this study, the CRF is used as the source
document for some clinical data points. Whenever possible,
clinical laboratory data (hematology/biochemistry, etc.) are
downloaded directly from the analyzers into the study
database.
All documents are stored safely in secure, confidential
locations. In order to maintain patient confidentiality,
only the signed informed consent form, the patient mas-
ter log, and the trial drug documents are labeled with
the patient’s name or identifying information. All other
study documents are identified by the subject number
and initials only. Data recorded on paper are entered on
site into the database in accordance with standard oper-
ating procedures and monitored for accuracy.
Where possible, patients admitted to the HDU/PICU
who might potentially be eligible for the study are moni-
tored on systems with the facility for subsequent auto-
matic download of hemodynamic parameters. If the
patient does enter the trial and gives appropriate con-
sent, then these data for up to 2 h prior to enrollment
are downloaded together with the information for the
72 h after enrollment.
Quality control and quality assurance procedures
The study will be conducted in accordance with the
current approved protocol, Viet Nam Guidelines for Good
Clinical Practice, and study standard operating proce-
dures. The OUCRU Clinical Trials Unit will be engaged in
assuring good governance, regulatory compliance, and
QA/QC of study execution. Any changes to study docu-
ments will be approved by the responsible ethics commit-
tee as required and communicated to all study staff by the
Principal Investigator before implementation.
Trial monitoring
The trial is being monitored according to procedures de-
fined by the OUCRU Research Governance Team to en-
sure that the rights and safety of patients are protected,
and that data are generated, documented, and reported
in compliance with the protocol, standard operating pro-
cedures, and the appropriate regulatory requirements.
Periodic onsite monitoring will take place to verify
source documents for study data quality and regulatory
compliance according to a risk-based monitoring plan.
Data sharing
The final data set will be anonymized and made available
through governed sharing mechanisms to external inves-
tigators for use in secondary analyses.
Statistical considerations
Sample size
During 2011, approximately one-third of patients with
Grade 3 HFMD managed at HTD (48/140, 34 %) and
CH1 (48/148, 32 %) required milrinone for ANS
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dysregulation with hypertension, and in 9/48 (19 %) of the
HTD cases and 10/48 (21 %) of the CH1 cases, milrinone,
when used alone, failed to control the hypertension (per-
sonal communication, Dr. Phan Tu Qui). Following intro-
duction of new Vietnamese MoH management guidelines
to commence intra-arterial BP monitoring early (at the
first sign of autonomic disturbance), among 16 children
managed in this way at HTD over a 2-month period, 12/
16 patients developed Stage 1 hypertension, and seven of
these 12 cases developed Stage 2 hypertension and were
treated with milrinone. Based on this observation (that is,
that 7/12 children with Stage 1 hypertension progressed),
for the sample size calculation for this study, we estimated
a progression rate of 50 % in the control arm.
With respect to the hypothesized treatment effect, lit-
tle direct information exists for the actual scenario we
plan to investigate, that is, the influence of MgSO4 com-
menced at Stage 1 hypertension on subsequent control
of SBP and progression to severe disease. In the case
series described earlier, when MgSO4 was added to the
treatment regimen of patients with poorly controlled
hypertension, despite high-dose milrinone, in all cases,
the SBP reduced within 30 to 60 min and thereafter
remained stable on a continuous MgSO4 infusion. In the
tetanus study mentioned above (in which the study drug
was given to patients with severe tetanus requiring a
tracheostomy), the requirement for additional therapy to
treat ANS dysfunction was reduced from 14/97 (14 %)
in the placebo group to 3/97 (3 %) in the MgSO4 group,
although the need for assisted ventilation was similar in
the two groups. Thus, indirect evidence suggests that
the effect size of the proposed intervention may be large;
we therefore estimate that use of MgSO4 could reduce
the risk of progression by > 50 %.
Based on 1:1 randomization, an anticipated relative
reduction in the risk of progression of 50 % (from 50 %
in the control arm to 25 % in MgSO4 recipients), 90 %
power, and a two-sided 5 % significance level, 85 patients
per treatment group are required. To allow for some
violations of our assumptions and losses to follow-up,
we plan to recruit 190 patients (95 patients per treat-
ment arm) into the study.
Statistical analysis
All planned statistical analyses will be pre-defined in a
detailed statistical analysis plan, which will be finalized
prior to unblinding the trial. The primary analysis popu-
lation will include all randomized patients who com-
menced the loading dose infusion of the study drug, and
analysis will be according to the randomized treatment
arm (intention-to-treat). A per protocol analysis will also
be performed, including all subjects who complete the
full treatment schedule for 72 h or if death or one of the
pre-specified criteria for stopping the study drug occurs
within 72 h. An additional analysis will also be per-
formed in the subgroup of patients with confirmed
EV71 infection. The primary endpoint of disease pro-
gression will be compared between the two treatment
arms based on logistic regression with the treatment
assignment as the only covariate. As disease progression
is evaluated in a short time frame, that is, within 72 h of
study drug initiation, we expect to lose only a minimal
number of patients to follow-up before that time point
and will analyze these patients according to their last re-
corded disease status. We will also perform regression
analysis, including a number of baseline covariates –
age, sex, BMI, day of illness at study entry, study site,
and baseline severity assessed in terms of an internation-
ally recognized score (PRISM III).
Predefined secondary endpoints and exploratory inves-
tigations will be compared between the two treatment
arms based on linear regression for continuous end-
points, logistic regression for binary endpoints, and Cox
regression for time-to-event endpoints. For laboratory
markers, analyses will be adjusted for the pre-dose value
of the respective marker. For host genetics analyses in
this sample, putative severity alleles will be detected by
filtering and comparison with reference data from con-
trol groups including the 1000 Genomes Project. For al-
leles with significant enrichment among severe cases,
validation will be attempted using samples from other
cohorts with severe HFMD.
The values for CO, SVR, catecholamine, and cytokine
measurements will also be correlated with clinical infor-
mation using descriptive statistical methods. Clinical in-
formation including temperature, skin perfusion,
capillary refill time, respiratory rate, and urine output
will be summarized for defined time intervals (6 hourly),
and relations will be assessed with the cardiovascular
and biochemical markers measured during the same
time interval.
All AEs and SAEs will be recorded in the patient CRF,
and reported to the relevant authorities as indicated pre-
viously. In addition, for analysis of safety endpoints, the
intensity of clinical and laboratory AEs are graded on a
five-point scale adapted from the NIH guidelines
(CTCAE version 4.03) [29] to ensure that the cutoffs
used are appropriate to the age of the population being
studied (Additional file 1: Appendix 10).
Ethical considerations
Ethical review
The study is being conducted in compliance with the
current revision of the Declaration of Helsinki (Seoul
2008) and the terms of approval of all supervising Eth-
ical Committees. The study protocol and its associated
documents have been reviewed and approved by the fol-
lowing committees: The Vietnam Ministry of Health’s
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Evaluation Committee on Ethics in Biomedical Research,
The Ethics Committee of the Hospital for Tropical Dis-
eases, The Science and Ethics Committee in Biomedical
Research of Childrens Hospital 1, and the Oxford Trop-
ical Research Ethics Committee (OxTREC, University of
Oxford). The study is managed by the OUCRU Clinical
Trials Unit in compliance with the ICH Guidelines of
Good Clinical Practice, the Vietnamese Ministry of
Health Guidelines of Good Clinical Practice and the
relevant institutional and regulatory requirements. The
study is sponsored by the University of Oxford and ap-
propriate insurance backed indemnity is in place with
respect to the University’s role as research sponsor.
Informed consent (Additional file 1: Appendix 7)
The study staff members discuss the study with the
accompanying parent/guardian, describing the purpose,
procedures, possible risks/benefits, the rights and
responsibilities of participants, and alternatives to enroll-
ment, and the family are invited to ask questions. Those
who agree to participate are asked to sign/date an
Informed Consent Form, with a second copy to keep.
As indicated above, because HFMD may progress rap-
idly, the parents/guardians of potentially eligible patients
are given study information shortly after admission, so
later if the child fulfils the necessary enrolment criteria,
the staff can discuss the study again, allowing the family
at least 1 to 2 h to decide. Families of children present-
ing with Stage 2 hypertension are given up to 30 min to
decide, but since insertion of the access lines necessary
for standard care takes at least 30 min, this process does
not result in delay. All families are given the opportunity
to review the study information on the PIS with a study
doctor at least once more 12 to 36 h after enrollment.
Confidentiality / participant protection
Personal information is recorded for the purpose of con-
sent and to enable follow up of treatment outcomes.
Access to identifying information is restricted to site-
specific study staff and the clinical care team, and only
anonymized data are entered into the study database. All
other study documents are identified by the subject
number and patient initials only. All documents are
stored safely in secure, confidential locations. Data re-
corded on paper are entered on site into the database in
accordance with standard operating procedures and are
monitored for accuracy.
Patient benefits & compensation
For all trial participants, the medical costs associated
with diagnosis and treatment of HFMD are covered
from the time that the parent/guardian agrees to allow
their child to enroll in the study until discharge but do
not include the medical costs related to previous
treatment decisions made before enrollment. All trial-
related procedures are covered by the study, and patients
are reimbursed the cost of local transport to attend for
the follow-up visit according to OUCRU compensation
policy. This policy reflects the actual cost of transporta-
tion plus modest compensation for time lost from work.
Withdrawal of participants from the study
Dedicated study staff members are employed to support
parents/guardians to meet study visits and ensure that
all trial outcome data are collected. Parents/guardians of
the study participants may voluntarily withdraw from
the study for any reason. If this occurs, the child will be
managed in accordance with standard clinical care
guidelines. With the agreement of the parent/guardian, a
clinical assessment will be performed and recorded at
the time of withdrawal, and the reason for withdrawal
will also be recorded in the CRF.
Communication/dissemination policies
The study protocol and materials will be made available
via publication. The results of the study will be reported
in international medical journals with authorship deter-
mined according to the guidelines of the International
Committee of Medical Journal Editors. Participants will
not be individually informed of the results. The overall
study findings will be published in both English and
Vietnamese and reported to the Department of Health
of Ho Chi Minh City. The researchers will also convey
the research results to the community in Vietnamese
through the OUCRU website and through talks and arti-
cles written and published in the mainstream media.
Safety reviews
An independent Data and Safety Monitoring Board
(DSMB) has been established, consisting of qualified in-
dividuals with the necessary knowledge of local treat-
ment guidelines, clinical trials, and statistics, and
operates in accordance with a written DSMB charter.
The DSMB reviewed and approved the conduct of the
study after enrollment of the first five, and subsequently,
the first 20 patients. In due course the DSMB will per-
form a formal safety review after 30 patients have been
enrolled (phase 1), including unblinded summary tables
of SAEs, AEs, or event reports submitted to the DSMB,
plus an analysis of overall clinical outcome based on the
interim analysis plan. If no safety concerns are identified,
recruitment will expand to include CH1 (phase 2). A
further DSMB review will take place after 100 patients
have enrolled in the study, with additional safety reviews
performed annually or at the discretion of the DSMB
based on available data and ongoing reporting. Unless
the benefit of MgSO4 is shown “beyond reasonable
doubt,” no formal stopping rule for efficacy is foreseen;
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the Haybittle-Peto boundary, requiring P < 0.001 at in-
terim analysis to consider stopping for efficacy, will be
used as a guide.
Discussion
Although HFMD has become a major contributor to
childhood morbidity and mortality in Vietnam, current
management strategies rely on guidelines that are based
primarily on expert opinion plus two small clinical
intervention studies, one of which used retrospective
controls. The efficacy of milrinone, an expensive drug
with a significant toxicity profile, for management of
ANS dysregulation in children with HFMD and brain-
stem involvement is unclear, and MgSO4, an alternative
therapeutic agent that is cheap, safe, and easily available
may be more effective.
The current Vietnamese MoH guidelines specify that
milrinone should be given to children with HFMD and
Stage 2 hypertension due to ANS dysregulation. Although
a direct comparison of MgSO4 with milrinone might have
been illuminating, we were constrained to ensure that
none of these very sick children be denied the possible
benefit of milrinone. Thus, enrollment to this study was
designed to be early, when hypertension is first identified
(at Stage 1), so that in the event of treatment failure, the
MoH treatment guidelines can still be applied. If MgSO4
is shown to be effective in controlling ANS dysregulation
at this early stage, and in preventing deterioration/devel-
opment of severe complications, this would be important
to pediatric care throughout the Asian region. Addition-
ally, it might be possible later to consider a direct com-
parison between milrinone and MgSO4 in HFMD cases
with established severe hypertension (Stage 2).
Sample size estimates for a study of this nature,
where reliable baseline outcome data are lacking, are
always difficult to calculate. We used indirect evi-
dence from use of MgSO4 in other conditions, to-
gether with the data from the small, unblinded pilot
study in severe HFMD cases that failed to respond to
maximum dose milrinone, to estimate the effect size
of the proposed intervention. We acknowledge that
the proposed effect size is large, but it does appear
reasonable based on this evidence. Moreover, given
the epidemic situation in Asia, we chose not to delay
starting the study further by doing a formal pilot
study.
Vietnamese guidelines for the management of
HFMD are regularly reviewed, and the MoH Guide-
lines Committee strongly supports the idea for this
study. If the results are positive, it is likely that use
of MgSO4 would be incorporated promptly into the
local guidelines, with the potential for rapid adoption
by neighboring countries experiencing similar severe
HFMD outbreaks.
Trial status
To date, 21 cases have been enrolled (July 2015), all
of whom survived and were discharged home. Long-
term follow-up is in progress for these cases. Interim
reports on the first five, and subsequently the first 20,
cases were reviewed by the DSMB, which approved
the conduct of the study and that no toxicity or dan-
ger signals were apparent in the data collected so far.
The Vietnamese MoH also audited the trial in April
2015 (as part of a planned review of all intervention
studies currently being performed at OUCRU) and
approved the study to proceed without modifications.
A formal interim analysis for safety is planned after
the first 30 patients have been enrolled.
This protocol is based on the approved version 1.6
dated 14 SEP 13, with additions according to publication
requirements.
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